Vaxcyte, a clinical-stage biopharma focused on pneumococcal conjugate vaccines, is progressing through key Phase 3 trials leveraging its XpressCF® cell-free protein synthesis platform. Despite no product revenue to date, it has maintained strong liquidity, bolstered by a $550 million public offering in early 2026. The company faces substantial operating losses driven by R&D investments, reliance on third-party CMOs, and regulatory uncertainties. Near-term milestones like OPUS-3 trial dosing and potential BLA submissions will be critical to validate its growth trajectory.